Found: 29
Select item for more details and to access through your institution.
A Multi-Arm Phase I Study of the PI3K/mTOR Inhibitors PF-04691502 and Gedatolisib (PF-05212384) plus Irinotecan or the MEK Inhibitor PD-0325901 in Advanced Cancer.
- Published in:
- 2017
- By:
- Publication type:
- journal article
A comprehensive examination of mental health in patients with head and neck cancer: systematic review and meta-analysis.
- Published in:
- JNCI Cancer Spectrum, 2024, v. 8, n. 3, p. 1, doi. 10.1093/jncics/pkae031
- By:
- Publication type:
- Article
Phase 1 Study of Molibresib (GSK525762), a Bromodomain and Extra-Terminal Domain Protein Inhibitor, in NUT Carcinoma and Other Solid Tumors.
- Published in:
- JNCI Cancer Spectrum, 2020, v. 4, n. 2, p. 1, doi. 10.1093/jncics/pkz093
- By:
- Publication type:
- Article
Overview of Oral Potentially Malignant Disorders: From Risk Factors to Specific Therapies.
- Published in:
- Cancers, 2021, v. 13, n. 15, p. 3696, doi. 10.3390/cancers13153696
- By:
- Publication type:
- Article
Digital Display Precision Predictor: the prototype of a global biomarker model to guide treatments with targeted therapy and predict progression-free survival.
- Published in:
- NPJ Precision Oncology, 2021, v. 5, n. 1, p. 1, doi. 10.1038/s41698-021-00171-6
- By:
- Publication type:
- Article
Phase I Trial of Cemiplimab, Radiotherapy, Cyclophosphamide, and Granulocyte Macrophage Colony‐Stimulating Factor in Patients with Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma.
- Published in:
- Oncologist, 2021, v. 26, n. 9, p. e1508, doi. 10.1002/onco.13810
- By:
- Publication type:
- Article
Clinical development of phosphatidylinositol 3-kinase inhibitors for cancer treatment.
- Published in:
- BMC Medicine, 2012, v. 10, n. 1, p. 161, doi. 10.1186/1741-7015-10-161
- By:
- Publication type:
- Article
Antitumour activity of neratinib in patients with HER2-mutant advanced biliary tract cancers.
- Published in:
- Nature Communications, 2023, v. 14, n. 1, p. 1, doi. 10.1038/s41467-023-36399-y
- By:
- Publication type:
- Article
Antitumour activity of neratinib in patients with HER2-mutant advanced biliary tract cancers.
- Published in:
- Nature Communications, 2023, v. 14, n. 1, p. 1, doi. 10.1038/s41467-023-36399-y
- By:
- Publication type:
- Article
Homologous Recombination Deficiency (HRD) as a Potential Pan-Cancer Biomarker for PARP Inhibition.
- Published in:
- Journal of Immunotherapy & Precision Oncology, 2024, v. 7, n. 3, p. 241, doi. 10.36401/JIPO-24-X2
- By:
- Publication type:
- Article
Phase I/II sequencing study of azacitidine, epacadostat, and pembrolizumab in advanced solid tumors.
- Published in:
- British Journal of Cancer, 2023, v. 128, n. 12, p. 2227, doi. 10.1038/s41416-023-02267-1
- By:
- Publication type:
- Article
First-in-human Phase 1 open label study of the BET inhibitor ODM-207 in patients with selected solid tumours.
- Published in:
- 2020
- By:
- Publication type:
- journal article
Public and patient involvement: a survey on knowledge, experience and opinions among researchers within a precision oncology European project.
- Published in:
- BMC Cancer, 2023, v. 23, n. 1, p. 1, doi. 10.1186/s12885-023-11262-x
- By:
- Publication type:
- Article
Confounding factors in the assessment of oral mucositis in head and neck cancer.
- Published in:
- Supportive Care in Cancer, 2022, v. 30, n. 10, p. 8455, doi. 10.1007/s00520-022-07128-w
- By:
- Publication type:
- Article
Pembrolizumab plus epacadostat in patients with recurrent/metastatic head and neck squamous cell carcinoma (KEYNOTE-669/ECHO-304): a phase 3, randomized, open-label study.
- Published in:
- BMC Cancer, 2024, v. 23, n. 1, p. 1, doi. 10.1186/s12885-023-11316-0
- By:
- Publication type:
- Article
Efficacy and safety of lurbinectedin and doxorubicin in relapsed small cell lung cancer. Results from an expansion cohort of a phase I study.
- Published in:
- Investigational New Drugs, 2021, v. 39, n. 5, p. 1275, doi. 10.1007/s10637-020-01025-x
- By:
- Publication type:
- Article
Phase I trial of dacomitinib, a pan-human epidermal growth factor receptor (HER) inhibitor, with concurrent radiotherapy and cisplatin in patients with locoregionally advanced squamous cell carcinoma of the head and neck (XDC-001).
- Published in:
- Investigational New Drugs, 2016, v. 34, n. 5, p. 575, doi. 10.1007/s10637-016-0367-2
- By:
- Publication type:
- Article
A first-in-human phase I trial of LY2780301, a dual p70 S6 kinase and Akt Inhibitor, in patients with advanced or metastatic cancer.
- Published in:
- Investigational New Drugs, 2015, v. 33, n. 3, p. 710, doi. 10.1007/s10637-015-0241-7
- By:
- Publication type:
- Article
Pharmacokinetic, pharmacodynamic and biomarker evaluation of transforming growth factor-β receptor I kinase inhibitor, galunisertib, in phase 1 study in patients with advanced cancer.
- Published in:
- 2015
- By:
- Publication type:
- Journal Article
Pharmacokinetic, pharmacodynamic and biomarker evaluation of transforming growth factor-β receptor I kinase inhibitor, galunisertib, in phase 1 study in patients with advanced cancer.
- Published in:
- Investigational New Drugs, 2015, v. 33, n. 2, p. 357, doi. 10.1007/s10637-014-0192-4
- By:
- Publication type:
- Article
A phase I trial of pantoprazole in combination with doxorubicin in patients with advanced solid tumors: evaluation of pharmacokinetics of both drugs and tissue penetration of doxorubicin.
- Published in:
- Investigational New Drugs, 2014, v. 32, n. 6, p. 1269, doi. 10.1007/s10637-014-0159-5
- By:
- Publication type:
- Article
Phase I dose-escalation and -expansion study of buparlisib (BKM120), an oral pan-Class I PI3K inhibitor, in patients with advanced solid tumors.
- Published in:
- Investigational New Drugs, 2014, v. 32, n. 4, p. 670, doi. 10.1007/s10637-014-0082-9
- By:
- Publication type:
- Article
A phase Ib combination study of RO4929097, a gamma-secretase inhibitor, and temsirolimus in patients with advanced solid tumors.
- Published in:
- Investigational New Drugs, 2013, v. 31, n. 5, p. 1182, doi. 10.1007/s10637-013-0001-5
- By:
- Publication type:
- Article
New clinical trial designs in the era of precision medicine.
- Published in:
- Molecular Oncology, 2019, v. 13, n. 3, p. 549, doi. 10.1002/1878-0261.12465
- By:
- Publication type:
- Article
Carlumab, an anti-C-C chemokine ligand 2 monoclonal antibody, in combination with four chemotherapy regimens for the treatment of patients with solid tumors: an open-label, multicenter phase 1b study.
- Published in:
- Targeted Oncology, 2015, v. 10, n. 1, p. 111, doi. 10.1007/s11523-014-0320-2
- By:
- Publication type:
- Article
Correction to: Recommendations for the use of biomarkers for head and neck cancer, including salivary gland tumours: a consensus of the Spanish Society of Medical Oncology and the Spanish Society of Pathology.
- Published in:
- 2023
- By:
- Publication type:
- Correction Notice
Recommendations for the use of biomarkers for head and neck cancer, including salivary gland tumours: a consensus of the Spanish Society of Medical Oncology and the Spanish Society of Pathology.
- Published in:
- Clinical & Translational Oncology, 2022, v. 24, n. 10, p. 1890, doi. 10.1007/s12094-022-02856-1
- By:
- Publication type:
- Article
Safety, pharmacokinetic, pharmacodynamic and clinical activity of molibresib for the treatment of nuclear protein of the testis carcinoma and other cancers: Results of a Phase I/II open‐label, dose escalation study.
- Published in:
- International Journal of Cancer, 2022, v. 150, n. 6, p. 993, doi. 10.1002/ijc.33861
- By:
- Publication type:
- Article
LIF regulates CXCL9 in tumor-associated macrophages and prevents CD8<sup>+</sup> T cell tumor-infiltration impairing anti-PD1 therapy.
- Published in:
- Nature Communications, 2019, v. 10, n. 1, p. N.PAG, doi. 10.1038/s41467-019-10369-9
- By:
- Publication type:
- Article